Chris is Chief Executive Officer and a Partner of Syncona Partners LLP. He is a seasoned biotech entrepreneur with over 30 years’ experience in the industry. From 2004 he served at the Chief Executive Officer of Argenta Discovery Ltd. (acquired by Galapagos NV in 2010) and later Pulmagen Therapeutics Limited. During this time, he successfully transitioned the company from early stage drug discovery to a mid-stage clinical development organisation. Chris has considerable expertise in leading and growing early stage companies and extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).

 Chris is Chief Executive Officer and a Partner of Syncona Partners LLP. He is a seasoned biotech entrepreneur with over 30 years’ experience in the industry. From 2004 he served at the Chief Executive Officer of Argenta Discovery Ltd. (acquired by Galapagos NV in 2010) and later Pulmagen Therapeutics Limited. During this time, he successfully transitioned the company from early stage drug discovery to a mid-stage clinical development organisation. Chris has considerable expertise in leading and growing early stage companies and extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).